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Abstract
Background—Fanconi Anemia (FA) is a rare genetic disorder resulting in a loss of function of 
the FA-related DNA repair pathway. Individuals with FA are predisposed to some cancers 
including oropharyngeal and gynecological cancers with known associations with human 
papillomavirus (HPV) in the general population. Since individuals with FA respond poorly to 
chemotherapy and radiation, prevention of cancer is critical.
Methods—To determine if individuals with FA are particularly susceptible to oral HPV 
infection, we analyzed survey-based risk factor data and tested DNA isolated from oral rinses 
from 126 individuals with FA and 162 unaffected first-degree family members for 37 HPV types.
Results—Fourteen individuals (11.1%) with FA tested positive, significantly more (p=0.003) 
than family members (2.5%). While HPV prevalence was even higher for sexually active 
individuals with FA (17.7% vs. 2.4% in family; p=0.003), HPV positivity also tended to be higher 
in the sexually inactive (8.7% in FA vs. 2.9% in siblings). Indeed, having FA increased HPV 
positivity 4.9 fold (95%CI: 1.6–15.4) considering age and sexual experience, but did not differ by 
other potential risk factors.
Conclusion—Our studies suggest that oral HPV is more common in individuals with FA. It will 
be essential to continue to explore associations between risk factors and immune dysfunction on 
HPV incidence and persistence over time.
Impact—HPV vaccination should be emphasized in those with FA as a first step to prevent 
oropharyngeal cancers, although additional studies are needed to determine if the level of 
protection it offers in this population is adequate.
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Introduction
Fanconi anemia (FA) is an inherited autosomal recessive or rare X-linked disorder 
characterized by genome instability, progressive bone marrow failure and predisposition to 
gynecological and head and neck squamous cell carcinomas (HNSCC). The risk of HNSCC 
is 1,000-fold greater compared to the general population, remains high even after bone 
marrow transplantation (BMT), and occurs at strikingly early ages with poor prognoses (1–
4). Human papillomavirus (HPV) infection, particularly HPV16, is known to be associated 
with HNSCC in the general population; specifically oropharyngeal cancers (5). 
Interestingly, HPV positivity was significantly higher in oral samples from individuals with 
FA living in Brazil than in non-FA controls (6) suggesting a role for HPV in FA-associated 
cancer. This report was consistent with an earlier United States (US)-based study that found 
HPV DNA prevalence to be significantly greater in 25 FA-related HNSCC tumors compared 
to non-FA controls (7). However, a Dutch study failed to detect HPV DNA in any of their 
FA-related tumors tested (8) and HPV was not detected in 5 HNSCC or 4 anogenital 
squamous cell carcinoma samples from subjects with FA in a more recent study (9). 
Therefore, the extent to which HPV is associated with FA or HNSCC in individuals with FA 
remains unclear. While HPV is commonly sexually transmitted, it has been detected in 
healthy children and virgin adults in a number of studies (10–12), likely as a result of 
horizontal (non-sexual, perinatal or parenteral) transmission. Better characterization of the 
natural history of oral HPV in the FA population is therefore needed.
FA is a consequence of mutations in one of 16 genes whose respective protein products 
assemble in the nucleus to repair DNA damage (13, 14). Our recent studies indicate that 
under normal circumstances, activation of this important DNA repair pathway limits the 
HPV life cycle and prevents malignant transformation. Specifically, loss of function of the 
FA-related DNA repair pathway in HPV positive keratinocytes stimulates cellular and viral 
DNA replication (15). Conversely, rescue experiments in cells obtained from individuals 
with FA reduced HPV-mediated DNA damage and suppressed tumor growth (16) indicating 
that FA DNA repair pathway deficient keratinocytes uniquely support HPV infection and/or 
replication. These findings are reinforced by studies in mice demonstrating that deficiencies 
in the FA DNA repair pathway are associated with an increased incidence of HNSCCs, and 
with the ability of the HPV E7 protein to induce DNA damage (17–19). In addition, recent 
immunophenotyping and immune function studies in ten children with FA suggest 
heterogeneous immune defects (20). The extent to which FA DNA repair pathway 
deficiency in keratinocytes and variable or inadequate immune cell function contributes to 
early HPV acquisition, maintenance and/or susceptibility to cancer remains unknown. Given 
that HPV vaccination has been shown to offer protection against some high risk HPV types 
in the general population, now is a critical time to investigate HPV in these vulnerable 
individuals to determine the need for earlier vaccination and to develop targeted treatments.
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In this study, we examined the prevalence of HPV infection in a sample of individuals with 
FA together with their parents who are obligate heterozygotes for the FA mutation, and 
siblings who are possible heterozygotes for the FA mutation. Study of family members 
helped to control for possibly non-sexual routes of exposure to HPV. Importantly, we 
observed a higher prevalence of HPV in individuals with FA as compared to their family 
members, particularly those that had been sexually exposed.
Materials and Methods
Informed Consent
This study was approved by Cincinnati Children’s Hospital Medical Center (CCHMC) 
Institutional Review Board. Briefly, following a detailed verbal description of the study, 
written informed consent/parental permission was obtained by a trained clinical research 
coordinator from participants’ ≥18 years old or participants’ parent(s)/legal authorized 
representatives. Participants that were ≥8 years old were asked to sign the consent document 
along with their parents/guardians to indicate their assent. Younger children or children 
unable to provide written assent indicated their assent by willingly providing their sample(s).
Participant Recruitment
Patients visiting the Cincinnati Children’s FA Comprehensive Care Center (CCFACCC) 
were approached to participate. Further, attendees of the Fanconi Anemia Research Fund 
(FARF) Adult and Family Meetings were invited to participate. Individuals of all ages were 
eligible to participate if they reported a diagnosis of FA or were a parent or sibling of an 
individual with FA, and were willing to complete study-related surveys and provide oral 
rinse samples. A subset (N=68) also provided a venous blood sample for HPV serology and 
immune studies. A total of 150 subjects with FA have been enrolled in the study as well as 
247 family members (biological siblings and parents). Of these, 126 individuals with FA, 41 
siblings and 121 parents currently have at least one HPV test result.
Oral Sample Collection, Nucleic Acid Isolation and HPV Testing
Oral exfoliated cells or oral-rinse and gargle samples were collected in 15 mL normal saline 
and 2.5 mL of 100% ethanol was added immediately after collection. Samples were stored 
for no more than 4 days at room temperature and then spun at 3,200 RPM for 10 minutes at 
4°C, the pellet washed in 10 mL of phosphate-buffered saline (PBS), spun again and 
resuspended in 1 mL PBS and stored in 500 µl aliquots at −80°C. In the laboratory of Darron 
Brown at Indiana University, DNA was isolated using the 5 Prime ArchivePure DNA kit (5 
Prime Inc., Gaithersburg, MD) according to the manufacturer’s protocol. DNA samples 
were genotyped by The Linear Array HPV Genotyping Test (Roche Molecular Diagnostics, 
Indianapolis, Indiana) (21). Reactions were amplified in a PerkinElmer TC9600 Thermal 
Cycler (PerkinElmer), and positive and negative controls (included in the assay) were 
performed with every polymerase chain reaction (PCR) run. The GH20/PC04 human β-
globin target was co-amplified to determine sample adequacy, and detection of specific HPV 
types was performed as previously described (22). The 37 individual HPV types detected are 
comprised of high risk HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 
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67, 68, 69, 70, 73, 82, and Subtype 82 W13B) and low-risk HPV types (6, 11, 40, 42, 54, 55, 
61, 62, 64, 72, 81, 83, 84, and 89).
Blood Collection, Processing and HPV Antibody Testing
Venous blood was collected observing appropriate aseptic techniques and universal 
precautions by trained personnel. Fifty percent were collected at the CCFACCC and 
immediately placed into storage at −80 degrees Celsius. Samples collected at FARF 
Meetings were typically kept at room temperature and centrifuged at 2,400 × g within 8 
hours of collection, aliquoted and then stored on dry ice until they were shipped via Same-
Day FedEx (N=20). Otherwise, they were shipped via Same-Day FedEx to CCHMC, 
centrifuged within 24 hours, aliquoted and stored at −80 degree Celsius (N=14). An aliquot 
of each serum (0.5–1mL typically) was sent via Next-Day FedEx for HPV serology testing 
in the HPV laboratory at the Centers for Disease Control and Prevention. The HPV4-plex 
virus-like particle (VLP)-based IgG enzyme-linked immunosorbent assay (ELISA) for HPV 
6, 11, 16 and 18 was performed as previously described (23). Cut-off values of Median+2 
standard deviations (SD) were calculated using children’s sera (Gift from Joakim Diller 
Karolinksa Institutet, Sweden) for each type. The pseudovirion neutralization assay (PBNA) 
was performed as described (24).
Immune assays
Humoral immune function was analyzed to assess effective or ineffective immune responses 
to HPV infection and or vaccination. Patient sera were tested for lymphocyte subsets, B cell 
panel, immunoglobulin levels (IgA, IgG, and IgM) along with tetanus and diphtheria titers. 
Immunoglobulin levels were determined by standard methods in the CCHMC clinical 
laboratory. Tetanus and diphtheria titers were determined by Quantitative Multiplex Bead 
Assay in the clinical diagnostic laboratory at CCHMC. Remaining assays were performed at 
the Diagnostic Immunology Laboratories at CCHMC. Results were interpreted with respect 
to age-appropriate reference ranges established in the laboratory. Peripheral blood 
mononuclear cells (PBMC) were isolated from heparinized blood by centrifugation with 
lymphocyte separation media (MP Biomedicals, Solon, OH, USA). Evaluation of patient 
lymphocyte subsets was performed via routine four-color flow cytometric analysis of EDTA 
preserved whole blood using fluorochrome-labelled monoclonal antibodies to lineage-
specific cell surface markers for T cells (CD3, CD4, CD8), B cells (CD19), and natural 
killer (NK) cells (CD16, CD56). All antibodies were obtained from BD Biosciences (San 
Jose, CA, USA). Briefly, erythrocytes were lysed by incubation in FACSLyse (BD 
Biosciences). Samples were then stained with antibody and analyzed on a FACSCalibur 
flow cytometer (BD Biosciences) using multiset software (BD Biosciences). Similar flow 
based approach was applied for assessment of B-Cell Panel (25).
Risk Factor Survey
Survey completion was done either by paper or by electronic survey (Research electronic 
data capture (REDCap) software) (26). Participants ages 15 years and older were asked to 
complete surveys for themselves unless there was a developmental delay, in which case a 
parent or guardian was asked to complete the survey. For children ages 12 to 15 years, a 
parent was asked either to complete the survey or assist the child in completing the survey. 
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However, answers to the sexual questions were ascertained by study staff interview 
whenever possible. Surveys collected demographic and clinical data including FA 
complementation group, disease severity, and date/age at bone marrow transplant (if any). In 
addition, other potential risk factors for HPV-related disease such as vaginal versus 
Cesarean section mode of delivery at birth, gestational age at birth, tobacco smoke exposure, 
alcohol consumption and sexual history (including questions about oral sex and kissing), 
family history of FA and cancer, history of personal immunization and/or HPV testing, and 
presence and frequency of oral lesions were ascertained by survey and/or staff interview. 
When available, biological mothers of participants were asked whether they have had genital 
or anal warts, a dysplastic Pap smear, or had a positive HPV test within a 3-year period 
before the birth of the individual(s) with FA and siblings.
Statistical Analysis
Statistical analyses were performed using Statistical Analysis Software (SAS), version 9.3 
(SAS Institute Inc., Cary, NC). Prior to analyses, data qualities were examined. 
Demographic variables and potential risk factors of HPV were first summarized as median 
and interquartile range (IQR) or frequencies (proportions) and compared in FA, siblings and 
parents. These factors were then compared between HPV negative and positive individuals 
with FA. Using Fisher’s exact tests, the impact of FA status on HPV prevalence was 
stratified by sexual experience or HPV vaccination status. Using a multi-variable logistic 
regression, we further tested the effects of HPV risk factors on the prevalence of HPV, 
adjusting for sexual experience, HPV vaccination status, and FA status in the model. Finally, 
the association between BMT and oral HPV was assessed considering HPV infection and 
sexual experience. Effects were considered significant if p-value ≤ 0.05.
Results
Population characteristics
A total of 288 individuals with oral rinse samples and risk factor questionnaires were 
included in this study. Of these, 126 individuals had FA, 121 were parents of individuals 
with FA (74 mothers and 47 fathers), and 41 were siblings of the individuals with FA (Table 
1). Participants with FA ranged in age from 6 months to 55 years. Family members’ ages 
ranged from 4 months to 79 years. As expected, ages were significantly different between 
subjects with FA and family members (p<0.0001). There were more females in each group 
than males, and more Caucasians than any other race. Individuals with FA were living in 
families across all income levels (26% <40K, 36% 40–90K, 39%>90K) and most had health 
insurance (32% public, 54% private and 11% had both public and private insurance) (Table 
1).
HPV prevalence in FA
Among those individuals with FA, 14 (11.1%) tested positive for one or more HPV types. 
Indeed, oral HPV positivity in FA was significantly greater than in non-FA family members 
(parents and siblings; 2.5%; p-value=0.003; Fisher’s exact test; Figure 1A), whose 
prevalence’s were consistent with published levels in the general population (range from 
1.9% to 7% (10–12)). Also consistent with published studies, the most common types of 
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HPV detected among those with FA were HPV 6 (50%) and HPV 16 (64%), although HPV 
18, 51, 66, 84 and CP6 were also detected. Only three of the HPV positive individuals with 
FA had previously been vaccinated for HPV (all receiving the GARDASIL Quadrivalent 
HPV Vaccine, Merck & Co., Inc., West Point, PA, USA) and of these three vaccinated HPV 
positive individuals, only a single person with FA tested positive for an HPV type included 
in the vaccine (HPV16). We also examined HPV positivity in people based on HPV vaccine 
history. As shown in Figure 1B, in both vaccinated and unvaccinated groups, individuals 
with FA tested positive for HPV more often. Importantly, in our study population, we 
observed significantly higher rates of vaccination in individuals with FA compared to family 
members (38% vs. 21% in siblings and 1% of parents, p<0.0001, Fisher’s exact test, Table 
2). It is therefore interesting that HPV prevalence is higher in FA despite greater rates of 
vaccination.
Typically transmission of high risk carcinogenic HPV types in the general population occurs 
predominantly via sexual contact including oral sex and open-mouthed kissing outside of 
vaginal sex (27). When we examined only those individuals who were sexually experienced, 
we observed significantly more oral HPV infections in those with FA (17.7%; p-value 
=0.003) compared to family members (2.4%; Figure 1C). In participants that were not yet 
sexually experienced, individuals with FA also tested positive for oral HPV (8.7%) more 
often compared to siblings (2.9%), though the difference did not reach statistical 
significance. We next assessed the effect of sex on the association between oral HPV 
positivity and FA. While having sex did not seem to increase HPV positivity in family 
members, individuals with FA exhibited a higher prevalence of HPV when they reported 
having had sexual experience (17.7% vs 8.7%), but this association again was not 
statistically significant at the 5% level. In multivariable logistic regression analysis 
including sexual experience, HPV vaccination and FA status, only having FA was 
significantly associated with oral HPV positivity (p=0.002). Indeed, having FA increased the 
odds of HPV positivity by 4.9 fold (95% CI: 1.6 –15.4). Greater HPV prevalence was 
observed in those with FA compared to family members regardless of age. Importantly, 
among those individuals with FA that were not sexually active, 7 children less than 13 years 
of age (10.9%) also tested HPV positive (Figure 1D).
Other potential between-group confounding or risk factors
We next evaluated several other factors associated with HPV positivity or HNSCC in the 
general population and compared those with FA to their family members (Table 2). We 
observed that 71% of individuals with FA compared to 54% of siblings and 90% of parents 
were delivered vaginally (p=0.0001; Table 2). The biological mothers of those with FA 
compared to sibling group as a whole were not more likely to have reported having an 
abnormal Pap smear, positive HPV test or other sexually transmitted disease within 3 years 
of their children’s birth (p=0.75). Not surprising given the differences in age as well as 
strength of the anti-smoking and anti-alcohol guidelines and education provided to those 
with FA by the Fanconi Anemia Research Fund (28), primary smoking and alcohol use were 
lower for those with FA and their siblings compared to parents (p=0.0003 and 0.0001, 
respectively; Table 2). While the frequency of genital warts and common warts did not 
significantly differ between groups (p=0.87 and p=0.81, respectively; Table 2), significantly 
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more individuals with FA reported oral sores (18%) compared to 8% of siblings and 4% of 
parents (p=0.006).
Examining only those individuals with FA, no other factor related to FA (complementation 
group, having had a transfusion or having a family history of cancer) or those known to 
contribute to HPV or HNSCCs (i.e. tobacco and alcohol use, oral, genital and common 
warts, and dental hygiene) were found to be significantly different between oral HPV 
positive or oral HPV negative individuals with FA in our study (Table 3). While some have 
hypothesized that BMT might be associated with the increased risk of HNSCC in 
individuals with FA, we found that HPV positivity was only slightly higher (12.7%) post-
BMT compared to pre-BMT (9.5%) and this association was not statistically significant 
(p=0.78; Figure 2). When we considered BMT and sexual experience simultaneously, we 
again observed higher levels of oral HPV positivity in those post-BMT particularly if they 
had had sexual experience, but again these differences were not statistically significant 
(p=1.0; Figure 2). Secondhand smoke exposure, however, was marginally statistically 
significantly higher in those that were oral HPV positive (29%) compared to oral HPV 
negative (9%; p=0.052).
Characterization of individuals with FA who are HPV positive
There was a broad range of ages (from 6 to 51 years of age) among the 14 individuals with 
FA who tested oral HPV positive (Table 3). Importantly, 7 (50%) were under the age of 13 
years and 8 individuals with FA indicated that they were not sexually active. The level of 
oral HPV positivity was similar for males and females and there were no differences by 
whether or not they had a BMT (57%). While 9 (64%) had the FANCA complementation 
group, C, F, I, and D2 complementation groups were also represented in those that tested 
oral HPV positive (Table 4). Only a single oral HPV positive participant (HPV 84) reported 
having had a diagnosis of oropharyngeal cancer prior to sampling.
Further, among all 8 oral HPV positive individuals with FA who had corresponding immune 
data, we observed 6 study participants to have normal IgG levels and 5 participants with 
normal absolute and/or memory B cells (Table 5). Most tetanus and diphtheria titers were 
also normal. Only 3 of the 8 subjects had been vaccinated for HPV prior to blood sampling. 
All vaccinated individuals had positive titers to all four HPV types included in the vaccine 
(all Gardasil) as well as normal tetanus and diphtheria levels (Table 5). Two of the oral HPV 
positive individuals who indicated that they had not yet been vaccinated for HPV were also 
serologically positive to types other than identified in their oral sample suggesting prior 
natural infections with these types. Three of the oral HPV positive participants had no 
detectable HPV titers. Two of these individuals tested positive for both oral HPV6 and 
HPV16. Interestingly, these individuals were either deficient in their absolute B cell count or 
memory B cells. Overall, there were no unifying characteristics that were shared by those 
that were oral HPV or serologically positive with FA. In fact, these data support our 
previous report that individuals with FA have heterogeneous immune responses (20).
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Discussion
Our cross sectional study demonstrates a higher frequency of oral HPV positivity in 
individuals with FA compared to family members. Further, while HPV prevalence was 
significantly higher for those with FA who reported sexual exposure compared to family 
members, HPV prevalence tended to also be higher in those who were not yet exposed to 
sex.
A possible role for HPV in FA (29) has been previously suggested following the report of 
higher prevalence of HPV in FA-related head and neck tumors (7). In contrast, another 
equally small study reported the absence of HPV in FA-related HNSCC tumors and cell 
lines derived from them (8). These opposing results may be due to experimental variability 
such as types of primers used, quality and content of DNA tested, analysis of tumors or 
tumor-derived cell lines, or geographic differences. More recently, Alter et al were unable to 
detect HPV in HNSCCs from individuals with FA (9). However, de Araujo et al. have 
shown an increased prevalence of oral HPV isolated from 42 oral cytobrush samples from 
individuals with FA without oral malignant lesions (6). One possibility is that the Brazilian 
population spanned a younger age range comparable to our study population. A second 
explanation for the discrepancy could be that some/many individuals with FA successfully 
clear the virus or suppress its replication before tumors develop, thus limiting detection in 
the tumors themselves. These studies, together with our data presented here, suggest that 
studies of the association between HPV and FA might have to be conducted on younger 
individuals, and call for continued longitudinal studies across the lifespan to determine if 
early life exposure to HPV impacts the development of HNSCCs in individuals with FA 
later in life. Further, longitudinal studies would better address potential routes of 
transmission outside of sexual exposure. We have currently not detected significant 
differences in breastfeeding, birthing method (c-section vs. vaginal), BMT/blood 
transfusions, and alcohol and tobacco exposure, although in some cases, the data collected 
was incomplete and likely underpowered to ascertain a true association.
While studies in human subjects remain controversial, there is growing evidence from cell 
lines, animal studies, expression analysis and computational biology approaches that support 
a strong association between the consequences of HPV infection in the context of deficiency 
in the FA proteins and development of cancer. Organotypic raft cultures of HPV-oncogene 
immortalized, FANCA deficient patient-derived keratinocytes demonstrate increased DNA 
damage, and excessive hyperplasia compared to FANCA complemented cell populations 
(16). In addition, the FA pathway seems to limit the ability of HPV to replicate in cultured 
keratinocytes (15). Indeed, FANCD2 deficient mice overexpressing the HPV E7 
oncoprotein have increased DNA damage and are more likely to develop HNSCCs (17) and 
cervical and vaginal cancer (18). These effects of E7 are due to inactivation of the Rb family 
of tumor suppressors that limit DNA damage (19). Microarray analysis of vulvar tissue 
infected with both low-risk and/or high-risk HPV types indicated that FANCA, FANCD2, 
and other DNA damage markers were significantly induced following high-risk HPV 
infection, along with increased DNA damage in the tissues (30). And finally, using a 
computational biology approach, a link between HPV16 and the FA DNA repair pathway 
was identified and then validated experimentally by evaluating the impact of overexpressing 
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E6 or E7 proteins in primary fibroblasts and keratinocytes using global gene expression 
analysis (31).
Together, these diverse approaches point to a common theme. It appears that HPV infection 
results in elevated DNA damage that then triggers the FA pathway to repair this DNA 
damage. In individuals where this pathway is defective, it is likely that the DNA damage 
will not be repaired, and as a consequence increases the likelihood of tumor development in 
the long term. It becomes important to consider these studies again in the context of the 
conflicting human data. Even if HPV is suppressed or cleared, and is undetectable by PCR 
assays, one might speculate that the resulting DNA damage is the trigger for increased 
HNSCCs and anogenital carcinomas many years later. Additional studies will be required to 
support this hypothesis.
Similar to the Brazilian study (6), we found that oral HPV16 was the most common type 
detected. We also detected less common HPV types in those with FA (36% of oral samples). 
It is plausible, although speculative, that less common high-risk types, or even low-risk HPV 
types, might unusually initiate a cancer cascade in those with FA who have both a DNA 
repair defect and heterogeneous immune deficiency, suggesting a need to evaluate the broad 
spectrum of HPV types rather than HPV16 and 18 alone in oral rinse and possibly other 
sample types. Indeed, among 67 throat swabs from individuals with FA collected at the 
same time as our oral rinse samples in this report, we identified 5 individuals positive for 
HPV 33, HPV 84, HPV 66, 51, 52, 62 82 and HPV 51; a 60% agreement between sample 
types (32).
An important variable to consider is the immune response to HPV infection in individuals 
with FA. We have previously demonstrated that individuals with FA have fewer B cells and 
NK cells, as well as decreased NK cell function and cytotoxic T cell activity (20). It is 
conceivable that in the absence of a fully functional FA pathway, the ability to suppress or 
clear HPV is also delayed. Based on the data from Table 5, there seems to be variability in 
the immune responses in HPV positive individuals with FA. While some subjects with FA 
had normal immune responses, others seem to be unable to mount a strong response (based 
on B cell and memory B cell numbers, IgG levels, and response to tetanus and diphtheria 
vaccines). These data indicate that while not all individuals with FA have measurably 
impaired immune responses, those that do could conceivably be at higher risk. It is 
reasonable to speculate that viral persistence due to the inability of the immune system to 
clear the infection or due to fluctuations in host immunity as a result of progressive bone 
marrow failure or FA-related illnesses, further increases the duration of HPV infection and 
extent of DNA damage, thereby resulting in an increased risk for carcinomas. Our data 
showed no differences in the type and distribution of factors known to cause cancers in 
individuals with Fanconi anemia regardless of their HPV infection status. This would further 
suggest that it might be the ability of the individual to suppress or clear the infection that 
most likely determines HPV prevalence, incidence, and susceptibility to HNSCCs.
In conclusion, continued longitudinal collection of oral samples and broad testing for HPV 
types along with immunological studies to better characterize response remains critical to 
address these questions. In addition, studies are needed to determine prospectively if HPV 
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infection is associated with increased HNSCCs in individuals with FA, and if vaccination at 
a younger age could be effective in preventing early infection.
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HPV human papillomavirus
HNSCC head and neck squamous cell carcinoma
FA Fanconi anemia
BMT bone marrow transplant
CCHMC Cincinnati Children’s Hospital Medical Center
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Key Points
– Increased oral HPV prevalence, particularly of HPV16, in individuals with 
Fanconi Anemia
– No obvious risk factors for oral HPV positivity among individuals with FA
– Those with FA have heterogeneous general immune responses and positive 
HPV serology
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Figure 1. 
Associations between oral HPV positivity in individuals with FA vs. their family members. 
A) Markedly greater oral HPV positivity considering all HPV-tested individuals with FA vs. 
their family members. B) Oral HPV positivity stratified by HPV vaccination (Gardasil). C) 
Oral HPV positivity stratified by sexual experience. Sex indicates that the participant 
reported having had sexual contact (oral, genital, and/or anal) via paper or online survey at 
the time of oral sampling. Those not having reported sexual contact are in the no sex group. 
D) Oral HPV positivity among those in the no sex group stratified by age. For all 
comparisons, Oral HPV positivity was determined by Roche Linear Array and the 
percentage of positive individuals are shown. A fisher’s exact test was used to assess 
statistical differences (2-sided p-values).
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Figure 2. 
Oral HPV positivity stratified by both history of bone marrow transplant (BMT) history and 
sexual experience. Oral HPV positivity was determined by the Roche Linear Array and the 
percentage of positive individuals are shown. BMT history was reported via paper or online 
survey at the time of oral sampling. Sex indicates that the participant reported having had 
sexual contact (oral, genital, and/or anal). Those not having reported sexual contact are in 
the no sex group. A fisher’s exact test was used to assess statistical differences (2-sided p-
values).
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